• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Forceps/Vacuum Delivery vs Cesarean Section and Adverse Maternal and Perinatal Outcomes

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • ACOG and SMFM are advocating operative vaginal delivery to reduce cesarean section rates
  • However, further research is needed on perinatal and maternal outcomes based on pelvic station
  • Muraca et al. (BJOG, 2017) sought to quantify risks associated with operative vaginal delivery at midcavity station

METHODS:

  • Population-based, retrospective cohort study from the British Columbia Perinatal Data Registry (2004-2014)
  • 37 to 41 week gestation singletons, 2nd stage of labor
  • Definition of operative ‘midcavity’ delivery
    • Operative vaginal delivery by forceps, vacuum and sequential instruments in cases where the head was engaged and the leading point of the fetal skull was above the +2 cm station but below the 0 cm station
  • Primary outcomes
    • Composite severe perinatal morbidity/mortality
    • Composite severe maternal morbidity
  • Propensity score methods and multivariable regression were used to account for confounders
  • Deliveries were stratified by indication – dystocia or fetal distress

RESULTS:

  • 10,901 deliveries: 5,057 attempted midcavity operative vaginal or caesarean deliveries with dystocia and 5,844 attempted midcavity operative vaginal or caesarean deliveries with fetal distress
  • Rate of severe perinatal morbidity/mortality was 1.42% (dystocia) and 2.34% (fetal distress)
  • The rate of severe maternal morbidity was 1.03% in both groups

Dystocia Indication

  • ‘Attempted’ midcavity operative vaginal delivery was associated with higher rates of severe perinatal morbidity/mortality compared with caesarean
    • Forceps: Adjusted rate ratio (ARR) 2.11, 95% CI 1.46–3.07
    • Vacuum: ARR 2.71, 95% CI 1.49–3.15
    • Sequential: ARR 4.68, 95% CI 3.33–6.58
  • Midcavity operative vaginal delivery was associated with higher maternal morbidity/mortality compared to cesarean
  • Forceps: ARR 1.57, 95% CI 1.05–2.36
  • Vacuum ARR 2.29, 95% CI 1.57–3.36

Fetal Distress Indication

  • ‘Attempted’ midcavity vacuum delivery was associated with higher rates of severe perinatal morbidity/mortality compared with caesarean (ARR 1.28, 95% CI 1.04–1.61)
  • ‘Attempted’ midcavity forceps delivery was associated with increased severe maternal morbidity compared to cesarean following (ARR 2.34, 95% CI 1.54–3.56)

CONCLUSION:

  • Attempted midcavity operative vaginal delivery is associated with higher rates of severe morbidity/mortality and severe maternal morbidity, dependent on indication and instrument
  • Maternal morbidity was mainly related to higher rates of postpartum hemorrhage
  • Obstetric and birth trauma rates were increased 2.8- to 8.5-fold following attempted vacuum delivery and forceps depending on indication and instrument
  • Authors recognize major limitation is non-experimental design
    • RCTs may not be feasible

Learn More – Primary Sources:

Perinatal and maternal morbidity and mortality among term singletons following midcavity operative vaginal delivery versus caesarean delivery

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Does Presence of Senior Obstetricians Impact Mode of Delivery?
Operative Vaginal Delivery or Repeat Cesarean Section During Trial of Labor
Does BMI Impact Success of Vacuum-Assisted Vaginal Delivery?
Vacuum Delivery – What is the Better Training Approach?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site